Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06956495 | Efficacy and Tolerability of Tasipimidine in Sleepless Patients | PHASE2 | COMPLETED | 190 | — | — | Aug 20, 2023 | Sep 24, 2025 | Oct 22, 2025 | 1 | Finland |
Assessed with polysomnography (PSG) for Day 1 and Day 2 data combined from Part 1 and Part 2
Assessed with polysomnography (PSG) for Day 1 and Day 2 data combined from Part 1 and Part 2
| Arm | Type | Description |
|---|---|---|
| Tasipimidine Dose level 1 | EXPERIMENTAL | Dose level 1 |
| Tasipimidine Dose level 2 | EXPERIMENTAL | Dose level 2 |
| Tasipimidine Dose level 3 | EXPERIMENTAL | Dose level 3 |
| Placebo | PLACEBO_COMPARATOR | Tasipimidine Placebo |
| Tasipimidine Dose level 4 | EXPERIMENTAL | Dose level 4 |
| Name | Type | Description |
|---|---|---|
| Tasipimidine | DRUG | Tasipimidine solution |
| Tasipimidine placebo | DRUG | Tasipimidine placebo solution |
Inclusion Criteria: * Signed informed consent (IC) for participation in the study. * Male or female subjects with age between 18 and 65 years. * Insomnia disorder * Self-reported history of the following on at least 3 nights per week and for at least 3 months prior to the screening: ≥ 30 minutes to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 3 | PHASE3 | Tasimelteon |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan , Astra-Zeneca |
| Unity Health Toronto | UBX | 1 | PHASE2 | Lemborexant |
| ResMed Inc. | RMD | 1 | NA | Undisclosed |
| IQVIA Holdings Inc | IQV | 1 | — | Daridorexant, Non-orexin receptor antagonist medications for insomnia |